A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: Subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study

被引:49
作者
Fonseca, V
Bell, DS
Berger, S
Thomson, S
Mecca, TE
机构
[1] Tulane Univ, New Orleans, LA 70112 USA
[2] Univ Alabama, Birmingham, AL USA
[3] Ctr Clin Res Inc, Chicago, IL USA
[4] VA Med Ctr, Tucson, AZ USA
[5] Quintiles Inc, Kansas City, MO USA
关键词
hypoglycemia; insulin analog; insulin glargine; NPH insulin; type; 2; diabetes;
D O I
10.1097/00000441-200411000-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Basal insulin is frequently administered once daily. This subgroup analysis of a multicenter, randomized, parallel study compared insulin glargine (Lantus Aventis Pharmaceuticals, Bridgewater, NJ) with neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes, evaluating only patients treated previously with once-daily NPH insulin. Methods: Patients received bedtime insulin glargine or NPH insulin, with preprandial regular insulin. One hundred patients (mean age, 57.9 years; mean glycohemoglobin, 8.4%; mean fasting blood glucose, 167 mg/dL) were treated for up to 28 weeks. Results: Patients treated with insulin glargine (n = 52) and NPH insulin (n = 48) achieved similar reductions from baseline in glycohemoglobin (-0.41% versus -0.46%) and fasting blood glucose (-22 mg/dL versus -22 mg/dL) at week 28. The proportion of patients reaching target fasting blood glucose (<120 mg/dL) at 28 weeks was 34.2% with insulin glargine and 24.4% with NPH insulin. Similar proportions of patients achieved glycohemoglobin less than 7% and less than 8% in both groups. Baseline and week-28 mean daily doses of insulin glargine (27.3 IU versus 36.4 IU) were similar to NPH insulin doses (25.5 IU versus 30.2 IU). However, significantly fewer patients reported one or more episodes of hypoglycemia with insulin glargine (46.2%) versus NPH insulin (60.4%; P < 0.05). Significantly fewer patients also reported one or more symptomatic episodes confirmed by blood glucose less than 50 mg/dL with insulin glargine (17.3%) versus NPH insulin (31.3%; P < 0.005). Conclusion: Bedtime insulin glargine is as effective as bedtime NPH insulin in improving glycemic control, with significantly less hypoglycemia.
引用
收藏
页码:274 / 280
页数:7
相关论文
共 19 条
[1]   Insulin - structure, function, design [J].
Brandenburg, D .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 :S6-S12
[2]   HYPOGLYCEMIA - THE LIMITING FACTOR IN THE MANAGEMENT OF IDDM [J].
CRYER, PE .
DIABETES, 1994, 43 (11) :1378-1389
[3]  
Cryer PE, 1999, DIABETES-METAB RES, V15, P42, DOI 10.1002/(SICI)1520-7560(199901/02)15:1<42::AID-DMRR1>3.0.CO
[4]  
2-B
[5]   Association of hypoglycemia and cardiac ischemia - A study based on continuous monitoring [J].
Desouza, C ;
Salazar, H ;
Cheong, B ;
Murgo, J ;
Fonseca, V .
DIABETES CARE, 2003, 26 (05) :1485-1489
[6]   Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes -: A randomized, controlled trial [J].
Fritsche, A ;
Schweitzer, MA ;
Häring, HU .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (12) :952-959
[7]   CONTROL OF GLYCEMIA [J].
GERICH, JE .
BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1993, 7 (03) :551-586
[8]   Global burden of diabetes, 1995-2025 - Prevalence, numerical estimates, and projections [J].
King, H ;
Aubert, RE ;
Herman, WH .
DIABETES CARE, 1998, 21 (09) :1414-1431
[9]   Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro [J].
Lepore, M ;
Pampanelli, S ;
Fanelli, C ;
Porcellati, F ;
Bartocci, L ;
Di Vincenzo, A ;
Cordoni, C ;
Costa, E ;
Brunetti, P ;
Bolli, GB .
DIABETES, 2000, 49 (12) :2142-2148
[10]   Insulins today and beyond [J].
Owens, DR ;
Zinman, B ;
Bolli, GB .
LANCET, 2001, 358 (9283) :739-746